Article info
PDFEditorial commentary
Noradrenergic therapies for apathy in Alzheimer’s disease?
- Correspondence to Professor Masud Husain, Nuffield Dept Clinical Neurosciences and Dept Experimental Psychology, Oxford University, Oxford, Oxfordshire, UK; masud.husain{at}ndcn.ox.ac.uk
Citation
Noradrenergic therapies for apathy in Alzheimer’s disease?
Publication history
- Received November 22, 2022
- Accepted November 23, 2022
- First published December 5, 2022.
Online issue publication
January 11, 2023
Article Versions
- Previous version (11 January 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.